ZIM Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
ZIM Laboratories has a total shareholder equity of ₹2.3B and total debt of ₹624.1M, which brings its debt-to-equity ratio to 27.6%. Its total assets and total liabilities are ₹3.7B and ₹1.4B respectively. ZIM Laboratories's EBIT is ₹249.0M making its interest coverage ratio 5. It has cash and short-term investments of ₹171.7M.
Key information
27.6%
Debt to equity ratio
₹624.12m
Debt
Interest coverage ratio | 5x |
Cash | ₹171.68m |
Equity | ₹2.26b |
Total liabilities | ₹1.40b |
Total assets | ₹3.66b |
Recent financial health updates
No updates
Recent updates
Earnings Not Telling The Story For ZIM Laboratories Limited (NSE:ZIMLAB) After Shares Rise 28%
Apr 26ZIM Laboratories Limited's (NSE:ZIMLAB) Shares May Have Run Too Fast Too Soon
Feb 20Estimating The Fair Value Of ZIM Laboratories Limited (NSE:ZIMLAB)
May 16Sentiment Still Eluding ZIM Laboratories Limited (NSE:ZIMLAB)
Nov 29Financial Position Analysis
Short Term Liabilities: ZIMLAB's short term assets (₹1.9B) exceed its short term liabilities (₹960.9M).
Long Term Liabilities: ZIMLAB's short term assets (₹1.9B) exceed its long term liabilities (₹436.3M).
Debt to Equity History and Analysis
Debt Level: ZIMLAB's net debt to equity ratio (20%) is considered satisfactory.
Reducing Debt: ZIMLAB's debt to equity ratio has reduced from 51.2% to 27.6% over the past 5 years.
Debt Coverage: ZIMLAB's debt is well covered by operating cash flow (84%).
Interest Coverage: ZIMLAB's interest payments on its debt are well covered by EBIT (5x coverage).